Five Topics That Shaped Japan Pharma In 2019
Strategic Corporate Moves Dominate
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
You may also be interested in...
Astellas pays to play in next-generation immuno-oncology through deal for young, privately held US venture and its novel modulation platform.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Japanese company joins the ranks of big pharma buying up gene therapy pioneers